ENGLEWOOD, Colo., March 6, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will postpone the release of its fourth quarter and full year financial results and conference call initially scheduled for Monday, March 6, 2023 at 4:15 p.m. ET.
The company will announce its fourth quarter and full year 2022 financial results and conference call schedule in a future press release to allow additional time to complete its year-end closing procedures.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufacturers, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com
Contact: Zynex, Inc. (800) 495-6670
Investor Relations Contact:
Gilmartin Group
Investor Relations Counsel
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$8.26 |
| Daily Change: | 0.15 1.85 |
| Daily Volume: | 63,204 |
| Market Cap: | US$262.170M |
October 24, 2024 September 04, 2024 September 03, 2024 July 25, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
